{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vasc:eds:celiprolol-evidence",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:16:00.000Z",
    "updated": "2026-01-07T03:16:00.000Z",
    "contributors": ["knowledge-graph-agent"],
    "confidence": 0.88,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/genetic-disorders",
    "type": "pharmacotherapy",
    "difficulty": "advanced",
    "importance": "high"
  },
  "content": {
    "title": "Celiprolol Evidence in Vascular EDS",
    "description": "Evidence for celiprolol therapy in reducing vascular events in vascular Ehlers-Danlos syndrome",
    "key_concepts": [
      {
        "concept": "Mechanism",
        "details": "Beta-blocker with vasodilating properties; may reduce arterial wall stress and improve collagen synthesis"
      },
      {
        "concept": "Clinical Trial",
        "details": "Ong et al. Lancet 2010 RCT showed 3-fold reduction in arterial events with celiprolol"
      },
      {
        "concept": "Dosing",
        "details": "Typically titrated to 400mg twice daily if tolerated"
      },
      {
        "concept": "Limitations",
        "details": "Small trial size, limited availability of celiprolol in some countries"
      }
    ],
    "clinical_significance": "Currently the only medication with RCT evidence for reducing vEDS complications"
  },
  "provenance": {
    "primary_sources": ["Ong KT et al. Lancet 2010"]
  }
}
